Morgan Stanley Starts BioMarin Pharmaceutical Inc. (BMRN) at Overweight
Tweet Send to a Friend
Morgan Stanley initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Overweight rating and a price target of $110.00.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
